**HUMAN B7.1 AND B7.2 CO-**STIMULATORY ANTIGENS

PATENT APPLICATION

## IN THE UNITED STATES PATENT AND TRADEMAN

Group Art Unit 1644 Inventor(s): **ANDERSON** Examiner: P. Gambel 746,361 Appln. No.: 08/ Atty. Dkt. 037003 0275943 Series Code ↑ Serial No. ↑ Client Ref Filed: November 8, 1996 Appln. Title: IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN Hon. Commissioner of Patents CERTAIN ANTIBODIES AND THE

Washington, D.C. 20231

Sir:

## REPLY/AMENDMENT/LETTER

Date: February 11, 2002

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

## FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim				AMO AO AMEN			
A.  NOT made B. Withdrawn C. made herewith D. made previously  For B & C See Required Separate Paper (Pat-256)	Claims remaining after amendment	Highest number previously paid for		Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
2. Total Effective Claims		**minus	0	0	x \$18/\$9 =	+ \$0	103/203
3. Independent Claims		***minus	0	0	x \$84/\$42 =	+ \$0	102/202
4. If amendment enters <u>proper</u> multiple dependent claim(s) into this application for <u>first</u> time (leave <u>blank</u> if this is a <u>reissue</u> application)					+ \$280/\$140 <sup>-</sup> =	LEE VALUE	104/204
6. Petition is hereby made to extend the original due (1 mo) \$110/\$55 =						12/20-	115/215
date to cover the date this response is filed for which the (2 mos) \$400/\$200 =					+ \$400	41/3	116/216
requisite fee is attached (3 mos) \$920/\$460 =					l c	YALUE	117/217
(Usable only for ≤ 2mo.OA 4 mos) \$1,440/\$720=					17.	18 110	118/218
(Usable <u>only</u> for 30 day/1mo.OA 5 mos) \$1,960/\$980=						6 200	128/228
7. Enter any previous extension fee paid since above original due date and subtract					- \$0	<del></del>	Market Control
8. Extension Fee Attached						d- + \$400	¥zze en 1 etc.
9. If <u>Terminal Disclaimer</u> attached, <u>add</u> Rule 20(d) official fee					+ \$110/\$5\$	+ \$110	148/248
10. If IDS attached requires Official Fee under Rule 97 (c),					+ \$180	+ \$0	126
or if Rule 97(d) Requestadd					+ \$180	- 1 30	126
11. After-Final Request Fee per rules 129(a) and 17(r)					+ \$740/370	+\$0	146/246
12. No. of additional inventions for examination per Rule 129(b)					x \$740/370 ea	+ \$0	149/249
13. Request for Continued Examination (RCE)					+ \$740/370	+ \$0	1179/1279
14. Petition fee for						+ \$0	
15. TOTAL FEE ENCLOSED =						= \$510	
16 *If the ontwike this areas is less than onto						L	

Our Deposit Account No. 03-3975) (Our Order No. 37003 0275943

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

35,030

Pillsbury Winthrop LLP Intellectual Property Group

1600 Tysons Boulevard McLean, VA 22102 Tel: (703) 905-2000

By Atty: Robin L. Teskin Sig:

Reg. No. Fax:

(703) 905-2500

Tel:

(703) 905-2200

Atty/Sec: RLT/AF

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments

<sup>16. \*</sup>If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

17. \*\*If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

<sup>18. \*\*\*</sup>If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

IN THE UNITED STATES PATENT AND FRADEMARK OFFICE

In re PATENT APPLICATION OF

ANDERSON.

Group Art Unit: 1644

Application No. 08/746,361

Examiner: P. Gambel

Filed: November 8, 1996

Title: IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTA

ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGE

RESPONSE TO OFFICE ACTION AND SUBMISSION OF SUBSTITUE TERMINAL DISCLAIMER

Hon. Commissioner of Patents Washington, D.C. 20231

Sir:

In response to the letter mailed by the Patent Office on January 7, 2002, Applicants submit herewith a substitute Terminal Disclaimer to overcome the double patenting rejection based on commonly assigned U.S. Patent 6,113,898.

Moreover, as discussed with Examiner Gambel, Applicants confirm that the §116 Response submitted on September 16, 2001 together with an unexecuted affidavit was intended to be construed as a complete §116 Response and Notice of Appeal in response to the final rejection mailed on January 16, 2002. Accordingly, it is believed that this case should now be in condition for allowance.

Response to Office Action U.S. Serial No. 08/746,361

Attorney Reference: <u>037003-0275943</u>

Page 2

Additionally, it would be greatly appreciated if, after receipt of this Action, the Examiner would confirm receipt of this Action and advise the status of the application in light of the §116 Reply.

Respectfully submitted, Pillsbury Winthrop LLP

Robin L. Teskin

Registration No. 35,030

1600 Tysons Boulevard McLean, Virginia 22102 (703) 905-2000 (703) 905-2500 Facsimile

Date: February 11, 2002

Attorney Reference: 037003/0275943